Reply - Letter to the Editor: Comment on "Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study.
Semaglutide gets more attention in the PCOS research arena this week. The team behind a recent pilot study on semaglutide plus metformin for weight and fertility outcomes in women with obesity and polycystic ovary syndrome (PCOS) just published their reply to a Letter to the Editor. The original study found that combining semaglutide with metformin offered promising effects on both weight loss and fertility markers for this tough-to-treat group.
Clin Nutr ESPEN
by Bolek T, Turňová P, Péč MJ et al.
“Reply - Letter to the Editor: Comment on "Effect of Semaglutide with Metformin for Weight Loss and Fertility in Polycystic Ovary Syndrome (PCOS) Patients with Obesity: A Pilot Prospective Study. Bolek T(1), Turňová P(2), Péč MJ(1), Ságová I(1), Jurica J(1), Samoš M(1). Author information: (1)Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic. (2)Gynecological and Prenatal Center Femray in Námestovo, Pavol Jozef Safarik University, Faculty of Medicine in Košice, Slovak Republic.”
Researchers from Slovakia’s Jessenius Faculty of Medicine doubled down on their results, addressing points raised in the comment. They clarified study methodology and reinforced their take: using semaglutide as an add-on to metformin could be a smart approach for PCOS-related obesity and reproductive challenges. This isn’t just about dropping pounds — it’s about improving hormonal balance and ovulation in a group that often struggles with standard care.
Key points from the reply:
The team stands by their measured use of semaglutide, keeping doses and safety in check for research purposes.
They pointed out the need for larger, longer studies. Their pilot results are just a start, but the early data supports further exploration.
The group welcomes debate and peer review, which keeps the PCOS peptide research community sharp and focused on what works.
For peptide researchers, this exchange is a clear signal: semaglutide isn’t just a metabolic tool, it’s being actively explored for its broader effects in reproductive health. If you’re sourcing semaglutide for similar studies, check out the semaglutide page for specs and suppliers.
Bottom line: expect more data on semaglutide and PCOS. The research community is just warming up.
Related Reading
Semaglutide 2·4 mg Found Safe and Effective in Patients With Overweight or Obesity
News · News-MedicalSemaglutide did more than cut weight in this analysis of 6,239 adults - News
News · Adv Drug Deliv RevEngineering peptide-drug conjugates for targeted cancer therapy: design principle, theranostic imaging, and translational challenges.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.